Literature DB >> 2869743

CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients.

A R Doran, D R Rubinow, A Roy, D Pickar.   

Abstract

Low levels of cerebrospinal fluid (CSF) somatostatin and abnormal response to dexamethasone are two neuroendocrine disturbances reported to appear in depression and other neuropsychiatric disorders. We measured the levels of CSF somatostatin in patients with schizophrenia (n = 44) and depression (n = 19). In view of in vitro and animal evidence of the ability of somatostatin to inhibit stimulated corticotropin secretion, we also administered the dexamethasone suppression test to a subgroup of the patients with schizophrenia (n = 16) and the total depressed group. Lower levels of CSF somatostatin were found in dexamethasone nonsuppressors regardless of diagnosis and were negatively correlated with maximum postdexamethasone cortisol level in the total and depressed patient groups. These data suggest a functional relationship between hypothalamic-pituitary-adrenal axis hyperactivity and reduced CSF somatostatin level.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869743     DOI: 10.1001/archpsyc.1986.01800040075011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  9 in total

1.  Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.

Authors:  J D Bremner; J Licinio; A Darnell; J H Krystal; M J Owens; S M Southwick; C B Nemeroff; D S Charney
Journal:  Am J Psychiatry       Date:  1997-05       Impact factor: 18.112

Review 2.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

3.  Somatostatin content and receptors in the cerebral cortex of depressed and control subjects.

Authors:  B G Charlton; A Leake; C Wright; A F Fairbairn; I G McKeith; J M Candy; I N Ferrier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

4.  The influence of human corticotropin-releasing hormone on somatostatin secretion in depressed patients and controls.

Authors:  K P Lesch; E Widerlöv; R Ekman; G Laux; R Rupprecht; H M Schulte; H Beckmann
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

5.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

6.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

Review 7.  Psychoneuroendocrine research in depression. II. Hormonal responses to releasing hormones as a probe for hypothalamic-pituitary-endorgan dysfunction.

Authors:  K P Lesch; R Rupprecht
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 8.  Sex differences and the neurobiology of affective disorders.

Authors:  David R Rubinow; Peter J Schmidt
Journal:  Neuropsychopharmacology       Date:  2018-07-09       Impact factor: 7.853

9.  A Natural History of Silent Brain Syndrome over 36 Years: A case report.

Authors:  Nathan Pirakitikulr; David T Tse
Journal:  Orbit       Date:  2021-03-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.